Top

Journal of Translational Medicine

Published in:

Open Access 01-12-2013 | Research

Notch signaling activation contributes to cardioprotection provided by ischemic preconditioning and postconditioning

Authors: Xue-liang Zhou, Li Wan, Qi-rong Xu, Yong Zhao, Ji-chun Liu

Published in: Journal of Translational Medicine | Issue 1/2013

Abstract

Background

Notch signaling is known to be activated following myocardial ischemia, but its role in cardioprotection provided by ischemic preconditioning (IPC) and ischemic postconditioning (IPost) remains unclear.

Methods

Lentiviral vectors were constructed to overexpress or knockdown N1ICD in H9c2 cardiomyocyte and rat heart exposed to ischemia reperfusion injury (IRI), IPC or IPost.

Results

Notch1 signaling was activated during myocardial IPC and IPost, and could enhance cell viability and inhibit apoptosis. Furthermore, activated Notch1 signaling stabilized mitochondrial membrane potential and reduced reactive oxygen species induced by IRI. The cardioprotection provided by activated Notch1 signaling resembled that of IPC and IPost, which was related to Stat3 activation and regulation of apoptosis related proteins. Furthermore, in langendorff heart perfusion model, activated Notch1 signaling restored cardiac function, decreased lactate dehydrogenase release and limited infarct size after myocardial ischemia. Conclusions: Notch1 signaling is activated and mediates cardioprotection provided by IPC and Ipost. Notch1 signaling may represent a potential new pharmacologic mimic for cardioprotection of ischemic heart disease.

Available only for authorised users

Minamino T: Cardioprotection from ischemia/reperfusion injury: basic and translational research. Circ J. 2012, 76: 1074-1082. 10.1253/circj.CJ-12-0132.CrossRefPubMed

Gerczuk PZ, Kloner RA: An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol. 2012, 59: 969-978. 10.1016/j.jacc.2011.07.054.CrossRefPubMed

Apostolakis E, Baikoussis NG, Papakonstantinou NA: The role of myocardial ischaemic preconditioning during beating heart surgery: biological aspect and clinical outcome. Interact Cardiovasc Thorac Surg. 2012, 14: 68-71. 10.1093/icvts/ivr024.PubMedCentralCrossRefPubMed

Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J: Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003, 285: H579-588.CrossRefPubMed

Huang C, Yitzhaki S, Perry CN, Liu W, Giricz Z, Mentzer RM, Gottlieb RA: Autophagy induced by ischemic preconditioning is essential for cardioprotection. J Cardiovasc Transl Res. 2010, 3: 365-373. 10.1007/s12265-010-9189-3.PubMedCentralCrossRefPubMed

Babiker FA, van Golde J, Vanagt WY, Prinzen FW: Pacing postconditioning: impact of pacing algorithm, gender, and diabetes on its myocardial protective effects. J Cardiovasc Transl Res. 2012, 5: 727-734. 10.1007/s12265-012-9390-7.CrossRefPubMed

Schwanbeck R, Martini S, Bernoth K, Just U: The notch signaling pathway: molecular basis of cell context dependency. Eur J Cell Biol. 2011, 90: 572-581. 10.1016/j.ejcb.2010.10.004.CrossRefPubMed

Kopan R: Notch signaling. Cold Spring Harb Perspect Biol. 2012, 4: 10-doi:10.1101/cshperspect.a011213CrossRef

Gude NA, Emmanuel G, Wu W, Cottage CT, Fischer K, Quijada P, Muraski JA, Alvarez R, Rubio M, Schaefer E, Sussman MA: Activation of notch-mediated protective signaling in the myocardium. Circ Res. 2008, 102: 1025-1035. 10.1161/CIRCRESAHA.107.164749.PubMedCentralCrossRefPubMed

10.

Kratsios P, Catela C, Salimova E, Huth M, Berno V, Rosenthal N, Mourkioti F: Distinct roles for cell-autonomous notch signaling in cardiomyocytes of the embryonic and adult heart. Circ Res. 2010, 106: 559-572. 10.1161/CIRCRESAHA.109.203034.CrossRefPubMed

11.

Croquelois A, Domenighetti AA, Nemir M, Lepore M, Rosenblatt-Velin N, Radtke F, Pedrazzini T: Control of the adaptive response of the heart to stress via the notch1 receptor pathway. J Exp Med. 2008, 205: 3173-3185. 10.1084/jem.20081427.PubMedCentralCrossRefPubMed

12.

Collesi C, Zentilin L, Sinagra G, Giacca M: Notch1 signaling stimulates proliferation of immature cardiomyocytes. J Cell Biol. 2008, 183: 117-128. 10.1083/jcb.200806091.PubMedCentralCrossRefPubMed

13.

Campa VM, Gutierrez-Lanza R, Cerignoli F, Diaz-Trelles R, Nelson B, Tsuji T, Barcova M, Jiang W, Mercola M: Notch activates cell cycle reentry and progression in quiescent cardiomyocytes. J Cell Biol. 2008, 183: 129-141. 10.1083/jcb.200806104.PubMedCentralCrossRefPubMed

14.

Lovschall H, Tummers M, Thesleff I, Fuchtbauer EM, Poulsen K: Activation of the notch signaling pathway in response to pulp capping of rat molars. Eur J Oral Sci. 2005, 113: 312-317. 10.1111/j.1600-0722.2005.00221.x.CrossRefPubMed

15.

Givogri MI, de Planell M, Galbiati F, Superchi D, Gritti A, Vescovi A, de Vellis J, Bongarzone ER: Notch signaling in astrocytes and neuroblasts of the adult subventricular zone in health and after cortical injury. Dev Neurosci. 2006, 28: 81-91. 10.1159/000090755.CrossRefPubMed

16.

Yang Y, Duan W, Jin Z, Bi S, Yan J, Jin Y, Lu J, Yang J, Yi D: New role of notch-mediated signaling pathway in myocardial ischemic preconditioning. Med Hypotheses. 2011, 76: 427-428. 10.1016/j.mehy.2010.11.011.CrossRefPubMed

17.

Hausenloy DJ, Ong SB, Yellon DM: The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol. 2009, 104: 189-202. 10.1007/s00395-009-0010-x.CrossRefPubMed

18.

Yu HC, Qin HY, He F, Wang L, Fu W, Liu D, Guo FC, Liang L, Dou KF, Han H: Canonical notch pathway protects hepatocytes from ischemia/reperfusion injury in mice by repressing reactive oxygen species production through jak2/stat3 signaling. Hepatology. 2011, 54: 979-98826. 10.1002/hep.24469.CrossRefPubMed

19.

Kinnally KW, Antonsson B: A tale of two mitochondrial channels, mac and ptp, in apoptosis. Apoptosis. 2007, 12: 857-868. 10.1007/s10495-007-0722-z.CrossRefPubMed

20.

Gao F, Yao M, Shi Y, Hao J, Ren Y, Liu Q, Wang X, Duan H: Notch pathway is involved in high glucose-induced apoptosis in podocytes via bcl-2 and p53 pathways. J Cell Biochem. 2013, 114: 1029-1038. 10.1002/jcb.24442.CrossRefPubMed

21.

Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, Schulz R: Cardioprotection by ischemic postconditioning is lost in aged and stat3-deficient mice. Circ Res. 2008, 102: 131-135. 10.1161/CIRCRESAHA.107.164699.CrossRefPubMed

22.

Obana M, Maeda M, Takeda K, Hayama A, Mohri T, Yamashita T, Nakaoka Y, Komuro I, Matsumiya G, Azuma J, Fujio Y: Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation. 2010, 121: 684-691. 10.1161/CIRCULATIONAHA.109.893677.CrossRefPubMed

23.

You L, Li L, Xu Q, Ren J, Zhang F: Postconditioning reduces infarct size and cardiac myocyte apoptosis via the opioid receptor and jak-stat signaling pathway. Mol Biol Rep. 2011, 38: 437-443. 10.1007/s11033-010-0126-y.CrossRefPubMed

24.

Hausenloy DJ, Lecour S, Yellon DM: Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: Two sides of the same coin. Antioxid Redox Signal. 2011, 14: 893-907. 10.1089/ars.2010.3360.CrossRefPubMed

Title: Notch signaling activation contributes to cardioprotection provided by ischemic preconditioning and postconditioning
Authors: Xue-liang Zhou
Li Wan
Qi-rong Xu
Yong Zhao
Ji-chun Liu
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue 1/2013
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/1479-5876-11-251

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Please log in to get access to this content

Other articles of this Issue 1/2013

Preserved endothelial function in human obesity in the absence of insulin resistance

Genetic mutations of GJB2 and mitochondrial 12S rRNA in nonsyndromic hearing loss in Jiangsu Province of China

Wound outcome in combat injuries is associated with a unique set of protein biomarkers

Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy

MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab

In silico approaches for designing highly effective cell penetrating peptides

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials